Overview 

Hyperlipidemia refers to a broad group of genetic and acquired conditions characterised by abnormally elevated levels of lipids in the bloodstream. It is a highly prevalent disorder, especially in Western countries, but its occurrence is widespread globally. Hyperlipidemia is defined as LDL, total cholesterol, triglycerides, or lipoprotein levels above the 90th percentile of the general population, or HDL levels below the 10th percentile. 

Blood lipids mainly include cholesterol, triglycerides, lipoproteins, chylomicrons, very low-density lipoprotein (VLDL), low-density lipoprotein (LDL), apolipoproteins, and high-density lipoprotein (HDL). The term hyperlipidemia generally indicates an increase in one or more plasma lipid components such as triglycerides, cholesterol, cholesterol esters, or phospholipids, as well as disturbances in plasma lipoproteins, including elevated VLDL and LDL or decreased HDL levels.

Since lipids are insoluble in plasma, they are transported as complexes called lipoproteins, and hyperlipidemia is often classified according to the specific lipoprotein abnormalities involved.^1,2

• Chylomicrons are rich in triglycerides, which carry dietary fats absorbed from the intestine
• Very low-density lipoproteins (VLDL) – Primarily transport triglycerides synthesised in the liver
• Intermediate-density lipoproteins (IDL) and low-density lipoproteins (LDL) – Cholesterol-dense remnants formed after triglyceride breakdown from VLDL
• High-density lipoproteins (HDL) -Transport cholesterol from peripheral tissues to the liver for excretion or recycling

Hyperlipidemia can also be broadly categorised into two main types: primary (familial) and secondary (acquired).

Primary (familial) hyperlipidemia

This form arises due to inherited genetic abnormalities and may be monogenic, involving a single defective gene, or polygenic, resulting from multiple genetic defects. Primary hyperlipidemia typically presents with distinct abnormal lipoprotein patterns, which can be identified through lipid profiling and are well-documented in classification systems.²

Secondary (acquired) hyperlipidemia

This type develops as a consequence of other medical conditions or external factors. Frequent causes include diabetes, nephrotic syndrome, hypothyroidism, chronic alcohol use, and certain medications, including corticosteroids, beta-blockers, and oral contraceptives. In some cases, secondary hyperlipidemia, particularly when associated with severe hypertriglyceridemia, may lead to complications such as acute pancreatitis.²

Symptoms of hyperlipidemia

Hyperlipidemia often progresses silently, without noticeable symptoms in its early stages. It is commonly identified only during routine health screenings or once it has advanced enough to contribute to serious complications such as stroke or heart attack.

Individuals with markedly elevated cholesterol levels, particularly those with inherited (familial) forms of the condition, may develop xanthomas. The cholesterol-rich deposits are noticed beneath the skin, frequently around the eyes or in other areas of the body.

Similarly, patients with significantly high triglyceride concentrations may develop multiple small, acne-like bumps (eruptive xanthomas) distributed across various sites.²

Complications of hyperlipidemia

Atherosclerosis

Hyperlipidemia is a major contributor to atherosclerosis, a process in which lipids, cholesterol, and calcium accumulate in medium- and large-sized arteries, forming fibrous plaques and narrowing the vessel lumen.² 

Coronary artery disease (CAD)

CAD results from atherosclerotic plaque buildup in arteries supplying the heart, restricting blood flow and oxygen delivery. Elevated cholesterol and triglycerides are strongly associated with the progression to coronary atherosclerosis. 

Myocardial infarction (heart attack)

A myocardial infarction occurs when blood flow to the heart is blocked, often due to plaque rupture and clot formation, resulting in ischemic injury. About one in four MI survivors has underlying hyperlipidemia. 

Ischemic stroke

An ischemic stroke arises when a clot or plaque fragment blocks a cerebral artery, reducing brain blood flow. Clinical trials show that reducing total cholesterol and LDL by ~15% significantly lowers first-stroke risk.

Epidemiology

Hyperlipidemia affects over three million adults in the US and Europe and is typically a chronic condition requiring lifestyle changes and pharmacologic treatment. Among individuals with premature CAD, the prevalence is 75–85% versus 40–48% in age-matched controls. Dyslipidemia is more common in whites than Blacks (women: 64.7% vs 49.5%; men: 78.4% vs 56.7%) and is more prevalent in men across all ethnicities. Countries with lower obesity and saturated fat intake report lower rates, while rare cases of secondary hyperlipidemia occur in children under two who are underweight or obese.¹

Treatment and management of hyperlipidemia 

Management of elevated LDL cholesterol is guided by overall Atherosclerotic Cardiovascular Disease (ASCVD) risk and involves discussion of therapy benefits and risks. Reducing LDL is highly effective in preventing atherosclerotic plaques and cardiovascular events. Lipid-lowering therapy is crucial for secondary prevention in those with established disease and also benefits high-risk individuals in primary prevention.¹

Lifestyle and initial interventions

For patients with mild hyperlipidemia and a low estimated 10-year ASCVD risk (<7.5%), first-line management consists of dietary modification and increased physical activity. Recommended measures include:¹

• Following a diet low in saturated fats and refined carbohydrates
• Restricting trans fats and limiting saturated fats to about 5% of total daily caloric intake
• Engaging in moderate-to-vigorous exercise (at least 30 minutes, 5–6 days per week)
• Smoking cessation, weight reduction, and blood pressure control to further reduce vascular risk

Pharmacological therapy

For those with moderate to high ASCVD risk (>7.5% 10-year risk), statins are the primary pharmacologic treatment of choice. Evidence from large meta-analyses indicates that lowering LDL cholesterol with statins reduces cardiovascular events—especially myocardial infarction—and can lower all-cause mortality in at-risk individuals.⁹

• Moderate-intensity statins: Lovastatin 40 mg, pravastatin 40 mg, simvastatin 40 mg, atorvastatin 10–20 mg, rosuvastatin 5–10 mg
• High-intensity statins: Atorvastatin 40–80 mg, rosuvastatin 20–40 mg
  

In clinical trials, moderate-intensity statin therapy produced a 20–30% reduction in cardiovascular events, with high-intensity therapy offering additional but comparatively smaller benefits.

Alternative and adjunctive therapies 

Patients unable to tolerate statins due to side effects or allergies may benefit from dose adjustment, switching to an alternative statin, or using other lipid-lowering agents.¹⁰ Ezetimibe and PCSK9 inhibitors, such as evolocumab, have shown significant LDL reduction, with PCSK9 inhibitors offering greater efficacy in certain statin-intolerant populations. Regular follow-up is essential to monitor response, adherence, and potential adverse effects, ensuring therapy remains tailored to the individual’s risk profile.^1,11

Gender differences in hyperlipidaemia presentation and treatment response

Sex differences in lipid and lipoprotein levels are evident from infancy through adulthood, with variations in both distribution and changes over time. These variations are particularly evident in inherited lipid disorders like familial hypercholesterolemia (FH), where high cholesterol levels are present from birth. 

In early life, girls tend to have higher low-density lipoprotein cholesterol (LDL-C) and total cholesterol compared to boys, while high-density lipoprotein cholesterol (HDL-C) remains similar between sexes. From early adulthood to middle age, women generally exhibit lower LDL-C and higher HDL-C levels, whereas men experience rising LDL-C and declining HDL-C. In older age, total cholesterol, LDL-C, HDL-C, and triglycerides decrease in both sexes, but the reduction is more pronounced in men. 

Reproductive milestones such as menstruation, pregnancy, breastfeeding, and menopause also affect women's lipid profiles. Lipid levels fluctuate throughout the menstrual cycle, and during pregnancy, both LDL-C and triglycerides increase significantly. For women with familial hypercholesterolemia, pregnancy has an added effect: statins must be discontinued, and the absolute LDL-C rise is greater than in women without FH. Menopause is associated with a shift toward a less favourable lipid profile. 

Therefore, it is crucial to consider both sex and life stage when interpreting lipid measurements. Although men are commonly perceived to have a more atherogenic profile, women exhibit less favourable lipid levels during infancy, early adulthood, and later life, with comparatively beneficial levels only during the premenopausal years (20–50). Despite the known influence of female reproductive stages on lipid metabolism, there remains a limited understanding of their precise impact.³

A Canadian study of the British Columbia FH Registry found that women (52.5%) were diagnosed later than men (45.5 vs 41.5 years), had higher HDL-C and lower triglycerides, but received less intensive lipid-lowering therapy. As a result, women had smaller LDL-C and apoB-100 reductions and were less likely to meet lipid targets (16.4% vs 33.3%). Although men had a higher absolute rate of premature MI, the relative risk was similar. The study highlights treatment disparities in women, possibly due to delayed diagnosis, reproductive considerations, and underuse of potent LLTs, though factors like multiparity and menopausal status were not assessed.⁴

Another study was conducted to investigate sex differences in lipid profiles and statin response in 322 pediatric patients with genetically confirmed heterozygous familial hypercholesterolemia (HeFH). At diagnosis, both boys and girls had elevated total cholesterol (TC) and LDL-C, with normal HDL-C and triglycerides. In a subgroup of 112 patients aged 8–17 years treated with statins for one year, girls had significantly higher TC, LDL-C, and triglycerides at baseline compared to boys. Statin therapy significantly lowered TC and LDL-C in both sexes, modestly increased HDL-C, and had no effect on triglycerides, with no significant sex differences in treatment response, though girls showed a slightly greater LDL-C reduction. These results highlight early sex-based disparities in lipid levels and the effectiveness of statins in pediatric HeFH patients.⁵

In another study, women were on average 3.5 years older than men and showed higher total cholesterol (TC) and HDL-C, lower triglycerides (TG), and a reduced TC/HDL-C ratio, whereas high TG and low HDL-C occurred twice as frequently in men. An inverse correlation between HDL-C and TG (r = −0.354, p < 0.001) was observed across the cohort, highlighting gender-associated differences in lipid profiles with potential implications for cardiovascular risk assessment and prevention.⁶

Among 389 women and 362 men with HoFH from 38 countries, median age at diagnosis (13 vs 11 years) and untreated LDL-C levels were comparable (579 vs 596 mg/dL). Smoking was more prevalent in men (27.2% vs 14.3%), and myocardial infarction was less frequent in women (8.0% vs 16.3%), with comparable mean ages at first event (39 vs 38 years). Treatment patterns, including statin use and lipoprotein apheresis, were similar between sexes. Sixteen years post-diagnosis, women had a lower cumulative MI incidence and trends toward lower all-cause and cardiovascular mortality, though the latter were not statistically significant.⁷

Summary

A frequent illness known as hyperlipidemia is characterised by high blood levels of lipoproteins, triglycerides, or cholesterol. Primary (genetic) or secondary (acquired) causes include diabetes, hypothyroidism, and certain medications. In severe situations, the illness may manifest as eruptive lesions or xanthomas, although it is usually asymptomatic. It dramatically raises the risk of coronary artery disease, myocardial infarction, ischemic stroke, and atherosclerosis if treatment is not received.

If you want to prevent and control, lifestyle modifications like quitting smoking, maintaining a healthy weight, exercising, and eating a balanced diet are crucial. Statins continue to be the mainstay of treatment, with PCSK9 inhibitors and ezetimibe as backups for instances that are resistant. There are numerous gender disparities; women are frequently identified later and receive less aggressive treatment, hence emphasizes the significance of individualised care. Reducing cardiovascular risk and enhancing long-term results require early detection and efficient treatment.